Lifitegrast is a medication used to treat dry eye disease. Lifitegrast is a FDA approved drug for the treatment of keratoconjunctivitis sicca (dry eye syndrome).
- Mechanism
- Curator reviewed
Lifitegrast binds to the integrin lymphocyte function-associated antigen-1 (LFA-1), a cell surface protein found on leukocytes and blocks the interaction of LFA-1 with its cognate ligand intercellular adhesion molecule-1 (ICAM-1). ICAM-1 may be overexpressed in corneal and conjunctival tissues in dry eye disease. LFA-1/ICAM-1 interaction can contribute to the formation of an immunological synapse resulting in T-cell proliferation/activation and migration to target tissues. In vitro studies demonstrated that lifitegrast may inhibit T-cell adhesion to ICAM-1 in a human T-cell line and may inhibit secretion of inflammatory cytokines, inflammatory mediators, chemokines, TNF-α, and IL-1 in human peripheral blood mononuclear cells.
- Primary indication
- For the treatment of signs and symptoms of keratoconjunctivitis sicca (dry eye syndrome).Curator reviewed · 1 structured indication
- Formula / weight
- C29H24Cl2N2O7S · 615.48 g/mol (avg)
- First approval
- Canada, 2024 · United States, 2016
- Code names
- SAR-1118 · SHP-606
- Brand names
Resolves to
JFOZKMSJYSPYLN-QHCPKHFHSA-NSMILESCS(=O)(=O)C1=CC(C[C@H](NC(=O)C2=C(Cl)C3=C(CN(CC3)C(=O)C3=CC=C4C=COC4=C3)C=C2Cl)C(O)=O)=CC=C1What you can answer from here — as of September 23, 2026
Which drugs share a target with Lifitegrast, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account